Weight loss typically continues, with clinical trials showing that semaglutide 2.4 mg (Wegovy) produces average weight loss of approximately 15% by week 68, while tirzepatide (Zepbound) has demonstrated weight loss of approximately 15-21% across different doses by week 72
Tirzepatide is a medication that targets two hormone pathways involved in appetite control and metabolic function
Diabetes Obes Metab 19(4):524536 Husain M, Bain SC, Holst AG, Mark T, Rasmussen S, Lingvay I (2020) Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
THE RESULTS Lose up to 20% of your total body weight after one year of medically-assisted weight loss with GLP-1 agonists
Vyvanse and Adderall are both FDA-approved stimulant medications for ADHD, but they work differently: Vyvanse is a prodrug that converts to dextroamphetamine after absorption, producing a gradual, long-lasting effect (10, 14 hours), while Adderall is a mixed amphetamine salt available in both immediate-release (4, 6 hours) and extended-release (8, 12 hours) forms
However, native GLP-1 has a limited half-life (1.55 min) due to its degradation by the enzyme Dipeptidyl peptidase 4 (DPP-4), necessitating the development of GLP-1 receptor agonists (GLP-1RAs) with longer activity (Campbell and Drucker 2013)